Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAMURAI 1901: S-1 + cisplatin chemoradiotherapy followed by durvalumab for unresectable stage III non-small cell lung cancer
jRCTs031190127Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2019
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, tegafur and cisplatin in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoint: 1-year progression-free survival rate. Started Dec 2019; status: completed.
02
Drugs
durvalumabtegafurcisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031190127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190127.